Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
-
Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Ahead of HBV Clinical Data
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral
-
Arbutus to Participate in Upcoming Investor Conferences
-
Arbutus to Participate in Upcoming Investor Conferences
-
Arbutus Biopharma (ABUS) PT Lowered to $5 at Chardan Capital Markets
-
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
-
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
-
Arbutus to Present at Chardan’s Genetic Medicines Conference
-
Arbutus to Present at Chardan’s Genetic Medicines Conference
-
Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy
-
Arbutus to Participate in Upcoming Investor Conferences
-
Pre-Open Movers 04/04: (GNCMA) (PRTK) (CYCC) Higher; (AYI) (KATE) (NVDA) Lower (more...)
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral; Safety Risk Overwhelms Promising Efficacy
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Amid Arrowhead Hepatitis B Program Discontinuations
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
-
Notable Analyst Rating Changes 7/8: (CF) (COF) (GFI) Upgraded; (AINV) (HUM) (ABUS) Downgraded
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Sell
-
UPDATE: Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
-
UPDATE: Notable Analyst Rating Changes 5/16: (NOK) (JCP) (BBT) Upgraded; (DB) (BLOX) (BITA) Downgraded
-
Chardan Capital Markets Starts Arbutus Biopharma (ABUS) at Sell